Examkin

Soru

Zorluk: OrtaEnd-of-Life and Palliative Care

For the following adult patients receiving end-of-life care, identify the most appropriate targeted pharmacologic therapy to manage their acute distressing symptoms.

  • An 82-year-old gentleman with severe idiopathic pulmonary fibrosis on maximal inhaler therapy and continuous supplemental oxygen who continues to experience agonizing breathlessness at rest.Prescribe a low-dose systemic opioid (e.g., oral or subcutaneous morphine).
  • A 69-year-old woman in the active phase of dying from glioblastoma who is unconscious and producing loud, gurgling respiratory noises that are deeply distressing to her spouse.Administer a muscarinic antagonist (e.g., sublingual glycopyrrolate or atropine).
  • A 58-year-old man with metastatic cholangiocarcinoma and newly oliguric acute kidney injury who develops diffuse myoclonus and severe allodynia while receiving high-dose intravenous hydromorphone.Transition to an analgesic lacking active neurotoxic metabolites (e.g., fentanyl or methadone).
  • A 75-year-old man with end-stage liver disease receiving home hospice care who begins striking at caregivers and screaming about intruders, completely refractory to environmental redirection.Administer a first-generation antipsychotic (e.g., haloperidol).

Cevap

The clinical scenarios are correctly paired with their specific symptom-directed therapies: the patient with dyspnea requires a systemic opioid, the patient with terminal secretions requires a muscarinic antagonist, the patient with opioid neurotoxicity and acute kidney injury requires opioid rotation, and the patient with agitated terminal delirium requires an antipsychotic.
Each clinical scenario presents a classic end-of-life symptom requiring a targeted pharmacologic intervention. Dyspnea is best managed with opioids to reduce the perception of breathlessness. Terminal secretions respond to anticholinergics that decrease fluid production. Opioid neurotoxicity in renal failure necessitates rotation to an opioid metabolized safely, like fentanyl. Severe agitated delirium is treated with antipsychotics when non-pharmacological interventions fail.

Adım Adım Çözüm

1
Evaluate the 82-year-old patient with refractory dyspnea.
Recognize that opioids are the gold standard for treating dyspnea at the end of life.
Opioids decrease the central respiratory drive and alleviate the sensation of air hunger.
2
Assess the 69-year-old patient with loud, gurgling respiratory noises.
Identify this as terminal secretions ('death rattle').
These secretions require anticholinergic drying agents, as suctioning is often ineffective and distressing.
3
Analyze the 58-year-old patient with myoclonus, allodynia, and acute kidney injury on hydromorphone.
Diagnose opioid-induced neurotoxicity due to metabolite accumulation.
Renal failure prevents the clearance of neurotoxic metabolites; the patient must be rotated to a renally safe opioid like fentanyl.
4
Evaluate the 75-year-old patient with hyperactive, aggressive behavior.
Diagnose terminal agitated delirium.
When non-pharmacologic measures fail, antipsychotics are required to manage severe agitation and ensure safety.

Anahtar Kavram

Pharmacologic management of terminal symptoms (dyspnea, secretions, delirium, opioid neurotoxicity) in end-of-life care
Bu soruyu puanla

Konular

End-of-Life and Palliative Care

Bu konudan daha fazla soru